EN
  • 业务咨询

    中国:

    Email: marketing@medicilon.com.cn

    业务咨询专线:400-780-8018

    (仅限服务咨询,其他事宜请拨打川沙总部电话)

    川沙总部电话: +86 (21) 5859-1500

    海外:

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在线留言×
点击切换
Customer Center
客户中心

研究人员设计并合成了一种光笼PI3K抑制剂1,它可以通过紫外线照射激活,释放出高效PI3K抑制剂2。化合物1和2的ADME研究通过美迪西进行

2023-07-05
|
访问量:

Aberrant activation of the PI3K pathway has been intensively targeted for cancer therapeutics for decades. In this work, researchers designed and synthesized a novel photocaged PI3K inhibitor 1, which could be readily activated by UV irradiation to release a highly potent PI3K inhibitor 2. 

ADME studies of compounds 1 and 2 were conducted by Medicilon

Medicilon's pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody.

53.png


Reference:

Kehui Zhang, et al. Design, Synthesis, and Biological Evaluation of a Novel Photocaged PI3K Inhibitor toward Precise Cancer Treatment. J Med Chem. 2021 Jun 10;64(11):7331-7340. doi: 10.1021/acs.jmedchem.0c02186. 

相关新闻
×
搜索验证
点击切换